Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
82 hedge funds and large institutions have $35.8M invested in Endocyte, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 26 reducing their positions, and 18 closing their positions.
726% more call options, than puts
Call options by funds: $289K | Put options by funds: $35K
8% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 26
5% less capital invested
Capital invested by funds: $37.8M → $35.8M (-$2.04M)
15% less funds holding
Funds holding: 96 → 82 (-14)
50% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.63M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$332K |
| 3 |
Renaissance Technologies
New York
|
+$330K |
| 4 |
AG
Algert Global
San Francisco,
California
|
+$310K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$138K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$1.18M |
| 2 |
JP Morgan Chase
New York
|
-$413K |
| 3 |
ERSOT
Employees Retirement System of Texas
Austin,
Texas
|
-$347K |
| 4 |
Millennium Management
New York
|
-$331K |
| 5 |
Morgan Stanley
New York
|
-$290K |
ECYT Hedge Fund Activity: Q1 2017 in Review
82 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q1 2017, worth a combined $35.8M — down 5.4% from $37.8M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ECYT and 9 opened new positions — a net loss of 9 holders — while 26 trimmed existing stakes and 28 added.
The largest buyer was BlackRock, adding an estimated $4.63M. The largest seller was Highland Capital Management (Texas), exiting entirely with an estimated $1.18M sold.
- 82 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q1 2017, down from 96 in Q4 2016.
- Funds reported $35.8M of Endocyte, Inc. Common Stock stock for Q1 2017, down 5.4% quarter-over-quarter.
- 9 funds opened new Endocyte, Inc. Common Stock positions in Q1 2017 and 18 closed out, a net change of -9 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q1 2017 was BlackRock, an estimated $4.63M added.
- The largest Endocyte, Inc. Common Stock seller in Q1 2017 was Highland Capital Management (Texas), an estimated $1.18M sold.
Based on aggregated 13F filings for Q1 2017.